PDCD1 and neoplasm: By calculating the tumor contribution to the largest connected component in the before- and on-treatment datasets, we showed that the on-treatment group indeed had generally lower tumor activity (Figure 5C), explainable by restored immune response in the tumor by blocking PD-1.44